Novartis Presents New Breast Cancer and Hematology Data at Major Medical Symposia
Novartis is set to present data from nearly 60 abstracts at the 2026 San Antonio Breast Cancer Symposium (SABCS) and 68th American Society of Hematology (ASH) Annual Meeting & Exposition. These presentations aim to reinforce Novartis's leadership in breast cancer and hematology, showcasing both approved medicines and a pipeline of next-generation therapies. Key highlights at SABCS include two late-breaking abstracts: a NATALEE nodal analysis providing long-term evidence for Kisqali, and the first clinical data presentation for SNV4818 (now RAE346) following its acquisition from Synnovation. At ASH, Novartis will feature eight oral presentations, including 144-week Phase III MANIFEST-2 results for investigational pelabresib. Andrea Myers, Global Head, Oncology Development, Ad Interim, Novartis, stated that the data reflect the company's commitment to advancing science for patients with cancer and serious blood disorders, deepening understanding of existing and investigational medicines, and exploring new ap...